Saturday, August 16, 2008

Current clinical trials/ recent trials quick hits August 2008

PRECISE Comit et al CIS and copaxone 481 patients 81 centers 1:1 randomization 3 years then open label robust effect on conversion to CDMS, black holes, EDSS data is pending.
FORTE study-- dosage study of copaxone 20 v. 40 mg 1155 patients 12 months negative  result
CHAMPS   (older study ) best prediictor of relapse is Gd++ lesions
BEYOND-- Betaseron 25v. Betaseron50 v. copaxone-- year two brain atrophy data was -.63, -.64 and -.59 respectively, favoring copaxone
REGARD  year two atrophy -.6% for rebif,-.5 % for copaxone favors copaxone but beware of pseudoatrophy effect in year one
CAREMS1 phase 3 Campath trial for naive early active patients
CAREMS2 phase 3 Campath trial for treatment failures on IFN who relapse with rrms 1200 patients
Freedoms  fingolimid, 2 doses .5 and 1.25 v placebo
Tranforms fingolimid v avonex
DEFINE BG12 fumarate dose finding 240 bid v tid
CONFIRM  fumarate v. comparator (which one?)
CLARITY  cladribine phase 3 pivotal fast track
ORACLE  cladribine trial for CIS
BRAVO  laquinomodv. placebo for rrms
OlympusRituxan v.placebo for PPMS failed trial in press
HERMES    Rituxan v. placebo for rrms reported in NEJM 2008
CAMMS223 Campath for RRMS phase 2 trial in press NEJM

Looking for a car that's sporty, fun and fits in your budget? Read reviews on AOL Autos.

1 comment:

Neurodoc said...

a compound that Serono just licensed to develop and market called ATX-MS-1467. Apparently, it is derived from MBP and is designed to induce tolerance of the body's t cells to autoantigens involved in MS. Very little info at this point....